Model Parameter Values and Ranges.

HCC = hepatocellular carcinoma; HCV = hepatitis C virus; IL-28B = interleukin-28B; NHANES III = Third National Health and Nutrition Examination Survey; PEG-IFN = pegylated interferon; PI = protease inhibitor; Rb = ribavirin; SVR = sustained virologic response; AE = adverse event; QALY = quality-adjusted life-year; CMS = Center for Medicare & Medicaid Services. For further details on parameter generation and the uncertainty distribution of parameters see Appendix S1 I; Appendix S1 I Table S2; Appendix S1 Table S3.*A high-risk individual is someone having a history of injection drug use, transfusion prior to 1992, or greater than 20 lifetime sex partners. The reported prevalence is estimated for the 1952–1961 birth cohort and include individuals both aware and unaware of their HCV infection status. We adjusted the prevalence to only include individuals unaware of their infection status in the cost-effectiveness analyses.& The mortality rates for people who recovered from HCV are adjusted by a linear combination of their mortality rates with HCV and mortality rates without HCV using a factor of 0.7.**The reported triple therapy effectiveness in the base-case is similar to boceprevir.***The total quality-of-life weight for a given age and HCV disease state is computed as the product of the mean age-specific quality weight obtained from published data [28], [29] and the utility associated with the HCV disease state minus any utility decrements for events that occurred during the cycle such as receiving treatment or a liver transplant.†Unlike other utilities in this table, these utility decrements are for short-term states (that is, receiving HCV treatment or a liver transplant). The QALY decrement for receiving HCV treatment involves multiplying the annual utility decrement by the time on treatment, which can vary given the response-guided therapy rules of each strategy. ˆOne time disutility applied in a 12 weeks period.‡The PI cost is added to the standard therapy cost while receiving triple therapy.|| The total costs for a given age and HCV disease state is computed as the sum of the mean age-specific health care costs [36] and the HCV-specific health state plus any costs of testing, treatment, or liver transplant that occurred in the cycle.¶We assumed costs in the recovered states are 50% of the hepatitis C–related care costs in the year before diagnosis of the corresponding unaware states [37].